Concentration effect relationship of CYP3A inhibition by ritonavir in humans

被引:42
作者
Eichbaum, Christine [1 ]
Cortese, Marianna [1 ]
Blank, Antje [1 ]
Burhenne, Juergen [1 ]
Mikus, Gerd [1 ,2 ]
机构
[1] Univ Heidelberg Hosp, Dept Clin Pharmacol & Pharmacoepidemiol, D-69120 Heidelberg, Germany
[2] Univ Heidelberg Hosp, Dept Internal Med Clin Pharmacol & Pharmacoepidem, D-69120 Heidelberg, Germany
关键词
CYP3A; Ritonavir; Inhibition; Midazolam; MECHANISM-BASED INHIBITION; ORAL MIDAZOLAM; CYTOCHROME-P450; PHARMACOKINETICS; CLEARANCE; PLASMA;
D O I
10.1007/s00228-013-1530-8
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
To investigate the dose and concentration dependency of CYP3A inhibition by ritonavir using the established limited sampling strategy with midazolam for CYP3A activity. An open, fixed-sequence study was carried out in 12 healthy subjects. Single ascending doses of ritonavir (0.1-300 mg) were evaluated for CYP3A inhibition in two cohorts using midazolam as a marker substance. Ritonavir administered as a single oral dose produced a dose-dependent CYP3A inhibition with an ID50 of 3.4 mg. Using the measured ritonavir concentrations an exposure-inhibition effect curve was established with an IC50 of 600 h pmol/L (AUC(2-4)). Over the ritonavir dose range studied non-linear exposure of ritonavir was observed. Ritonavir shows a dose and concentration effect relationship of CYP3A inhibition. In addition, a proposed auto-inhibition of ritonavir metabolism resulted in a non-linear exposure of ritonavir with sub-proportional concentrations at low doses. A time-dependent CYP3A activity may result when inhibitors of CYP3A with short elimination half-lives are used.
引用
收藏
页码:1795 / 1800
页数:6
相关论文
共 23 条
[1]   Effect of extended exposure to grapefruit juice on cytochrome P450 3A activity in humans: Comparison with ritonavir [J].
Culm-Merdek, KE ;
von Moltke, LL ;
Gan, L ;
Horan, KA ;
Reynolds, R ;
Harmatz, JS ;
Court, MH ;
Greenblatt, DJ .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 79 (03) :243-254
[2]  
European Medicines Agency, 2012, NORV EMEA H C 000127
[3]   Effect of the CYP3A inhibitor ketoconazole on the PXR-mediated induction of CYP3A activity [J].
Fuchs, Ines ;
Hafner-Blumenstiel, Verena ;
Markert, Christoph ;
Burhenne, Juergen ;
Weiss, Johanna ;
Haefeli, Walter Emil ;
Mikus, Gerd .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 69 (03) :507-513
[4]   Neither dapsone hydroxylation nor cortisol 6β-hydroxylation detects the inhibition of CYP3A4 by HIV-1 protease inhibitors [J].
Gass, RJA ;
Gal, J ;
Fogle, PW ;
Detmar-Hanna, D ;
Gerber, JG .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 54 (9-10) :741-747
[5]   Inhibition of oral midazolam clearance by boosting doses of ritonavir, and by 4,4-dimethyl-benziso-(2H)-selenazine (ALT-2074), an experimental catalytic mimic of glutathione oxidase [J].
Greenblatt, David J. ;
Peters, Diane E. ;
Oleson, Lauren E. ;
Harmatz, Jerold S. ;
MacNab, Malcolm W. ;
Berkowitz, Noah ;
Zinny, Miguel A. ;
Court, Michael H. .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 68 (06) :920-927
[6]  
Greenblatt DJ, 2000, J ACQ IMMUN DEF SYND, V24, P129
[7]   Cytochrome P450 and chemical toxicology [J].
Guengerich, F. Peter .
CHEMICAL RESEARCH IN TOXICOLOGY, 2008, 21 (01) :70-83
[8]   Effect of Simultaneous Induction and Inhibition of CYP3A by St John's Wort and Ritonavir on CYP3A Activity [J].
Hafner, V. ;
Jaeger, M. ;
Matthee, A-K ;
Ding, R. ;
Burhenne, J. ;
Haefeli, W. E. ;
Mikus, G. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 87 (02) :191-196
[9]   How much ritonavir is needed to boost protease inhibitors? Systematic review of 17 dose-ranging pharmacokinetic trials [J].
Hill, Andrew ;
van der Lugt, Jasper ;
Sawyer, Will ;
Boffito, Marta .
AIDS, 2009, 23 (17) :2237-2245
[10]   Ritonavir - Clinical pharmacokinetics and interactions with other anti-HIV agents [J].
Hsu, A ;
Granneman, GR ;
Bertz, RJ .
CLINICAL PHARMACOKINETICS, 1998, 35 (04) :275-291